Future kidney cancer treatments show promise (w/VIDEO)
December 21, 2013 | by Denise Heady
Treatments for kidney cancer have improved dramatically over the past few years — particularly for renal cell carcinoma, the most common type of kidney cancer. And the future looks bright as well.
Treatment for cancer of the kidneys (shown here) is improving, with more advances expected.
The Food and Drug Administration has approved seven new drugs for the treatment of renal cell carcinoma, especially significant because it approved only one drug between 1992 and 2005. Further, targeted therapies are improving standard care for patients with the disease, and several promising studies could lead to new treatment advances.
Sumanta Kumar Pal, M.D., co-director of the Kidney Cancer Program at City of Hope, summed up the field in a recent interview with OncLive. “This is so incredibly promising for patients and their families,” he said of the recent developments.
But, as with most cancer treatments, new, innovative approaches are always needed.
“What I think the field is really lacking is that there are no novel approaches,” Pal said in the interview. “So I’m really looking for trials with PD-1 inhibitors, PD-L1 inhibitors, and novel dual-targeting agents such as cabozantinib to really reshape the treatment paradigm for this disease.”
No comments:
Post a Comment